Leading Beyond The Lab

25 years of life sciences venture experience in one episode.This week on Leading Beyond The Lab, @Lawrence Rose sat down with @Joey Mason, a venture investor with 25 years of experience across venture debt, venture capital and company building. Joey’s background spans senior roles with @Claret Capital Partners, @Sofinnova Partners, and earlier positions in investment banking and CRO services. His track record includes multiple successful exits, advising boards, working across Medtech, Biotech, digital health and Techbio, and supporting companies through regulatory approval, clinical development and commercial scale.In this episode, Joey covers:Joey dives into his career spanning 25 years of Life Sciences experience, from early biotech to leading global investment firms.He unpacks the frameworks and philosophies that guide his investment decisions across the Life Sciences ecosystem.Joey reflects on a standout investment, what made it succeed, and the lessons it offers future founders.A candid discussion on what strong leadership looks like in high-growth Life Sciences ventures.Joey shares exactly what he looks for in a pitch, and what turns him off instantly.Looking ahead, Joey reveals where he’s placing bets and what excites him most about the next wave of Life Sciences innovation.Check out this episode if you want a grounded, practical understanding of how life sciences companies are assessed, funded and supported behind the scenes, and how founders can communicate, hire and plan more effectively on the path to scale.Follow ARTO!LinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentLawrence RoseCo-Founder + Talent Solutions Director at @ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Joey MasonVenture Advisor @SofinnovaVenture Partner @Claret Capital PartnersLinkedIn: https://www.linkedin.com/in/joey-mason/Timestamps01:09 Joey’s Career05:14 Investment approaches19:17 Most successful investment28:20 Leadership32:46 How to pitch to Joey Mason42:21 Future plans#LeadingBeyondTheLab #ARTOTalent #LifeSciences #VentureCapital #VentureDebt #Medtech #Biotech #TechBio #DigitalHealth #IrelandEcosystem #Pharma #InvestmentStrategy Hosted on Acast. See acast.com/privacy for more information.

🤔 What does it really take to build a biotech that survives the clinical gauntlet and scales into a global business?🎬 This week on Leading Beyond The Lab, Lawrence Rose sat down with Roel Bulthuis, Managing Partner and Head of Investments at Syncona Limited. Roel has spent his career building, funding and scaling European biotech companies end-to-end, supporting high-performing teams from inception through clinical development, commercial launch and manufacturing scale-up. Along the way he references outcomes from portfolio companies such as Autolus Therapeutics and Beacon Therapeutics, showing how patient capital and conviction-led strategy compound over time.⭐️ Syncona has an impressive portfolio including,Autolus Therapeutics, Beacon Therapeutics, Spur Therapeutics, iOnctura, Quell Therapeutics, ANAVEON AG, MOSAIC THERAPEUTIC SERVICES, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics.🚀 In this episode, Roel dives into:- What defines a Syncona company and its unique model- Key lessons learned from both successes and setbacks- How to manage investor involvement without stifling progress- The challenges of leadership transitions within portfolio companies- Syncona’s strategic commitment to the European market- What drives Roel personally and what he enjoys most about his roleCheck out this episode if you want grounded insight into biotech venture building, long-term capital strategy and how scientific founders scale from the lab to patient impact. 🤝Follow ARTO!LinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.comYoutube: https://www.youtube.com/@life_sciences Lawrence RoseCo-Founder + Talent Solutions Director at @ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Role BulthuisManaging Partner @SynconaLinkedIn: https://www.linkedin.com/in/roel-bulthuis-aa414a/Timestamps:01:10 What makes up a Syncona company?11:25 What were the main lessons learnt from previous failures/successes?15:06 Managing investor involvement & preventing counter productivity.22:14 The issues with exchanging leadership.31:07 Commitment to the European Market.42:20 What Roel enjoys about his job. Hosted on Acast. See acast.com/privacy for more information.

A once-in-a-century transformation, and the leader driving it.This week, in one of our biggest episode of Leading Beyond the Lab yet, we sit down with Christophe Bourdon, CEO of LEO Pharma, a company valued in the multi-billion-euro range and entering one of the most defining chapters in its 100-year history.With over 25+ years of global biopharma leadership experience, spanning pivotal roles at Amgen, Sanofi, and Orphazyme, Christophe brings a rare combination of commercial excellence, turnaround leadership, and global market insight. He also shares how senior leaders such as Murdo Gordon helped shape his approach to building high-performing, people-centric teams.In this episode, Host of Leading Beyond The Lab, @Lawrence Rose, discusses with Christophe how he’s reshaping a century-old European company into a modern, innovation-driven global leader, covering:Transforming LEO Pharma, from financial urgency to sustainable growth, cultural renewal, and long-term clarity.The Partner and Development model, and why global players like Gilead Sciences and Boehringer Ingelheim have chosen LEO as a trusted innovation partner.Leadership and culture at scale, transparency, conviction, rebuilding confidence, and empowering bold talent.Preparing for a future IPO, aligning profitability, growth, and a clear 5-year vision for employees, shareholders, and partners.Europe vs. the US in the next decade of biotech, why the US has become LEO’s largest affiliate and what this shift means for global competitiveness.This episode is a rare look at what it truly takes to modernise a legacy company while keeping innovation, collaboration, and leadership at the core.Be sure to check out this episode - one of our most important conversations to date.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentChristophe BourdonCEO of LEO PharmaLinkedIn: https://www.linkedin.com/in/christophe-bourdon-77a62b6/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 LEO’S Recent Achievements06:58 Shaping a Modern LEO Pharma16:30 LEO Pharma’s IPO Journey25:39 Christophe’s Leadership Hosted on Acast. See acast.com/privacy for more information.

What does it take to shape a high-impact biotech investment portfolio - and do it under a medical charity mandate?This week we sit down with Clare Terlouw, Head of LifeArc Ventures, whose 20+ year career spans investment banking, biotech company building, and leading venture teams focused on health innovation. With a unique perspective at the intersection of science, capital, and patient impact, Clare shares a candid and optimistic view of the evolving biotech landscape in the UK and beyond.In this episode, Clare covers:- LifeArc Ventures’ mission: how a medical charity is driving returns while staying true to a patient-first vision.- Investing and scaling biotech: from early inflection points to Series B and beyond, what great companies get right.- Biotech in the UK: challenges in the current funding environment, the talent surge, and why optimism still holds.- Tech-enabled drug discovery: how AI, computational biology, and new business models are shaping investment priorities.- Clare's leadership lens: her personal drive, how she evaluates opportunity, and the power of staying focused on patient outcomes.Be sure to check out this episode if you're interested in the future of biotech investing, the rise of tech-enabled therapeutics, and how one venture leader is backing science that matters.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.comYoutube: https://www.youtube.com/@life_sciencesClare TerlouwManaging Partner at Life ArcLinkedIn: https://www.linkedin.com/in/clare-terlouw-b608aa17/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Life Arc - Investments + Impact 09:44 Investing in and Growing a Company17:52 Biotech in the UK26:18 Tech Enabled Drug Discovery32:57 Clare Terlouw Hosted on Acast. See acast.com/privacy for more information.

If you're not paying attention to nuclear medicine, Danielle Meyrick will change that in under five minutes.This week, we sit down with Dr. Danielle Meyrick, Director and Co-Founder at EPIC Theranostics, to explore the meteoric rise of nuclear medicine and radiotheranostics. With over 20 years of experience spanning academia, biotech, and hospital environments, Danielle is uniquely positioned as both a scientific pioneer and commercial strategist. Her career has spanned from launching radiopharmaceutical therapies in hospitals to shaping global strategies for biotech companies. If you're serious about understanding the future of oncology, this is the episode to watch. In this episode we cover:Why nuclear medicine is having a moment - and what makes radiotheranostics the most promising modality in oncology today.From PhD to MD – Danielle’s unconventional path to medicine, and how her dual perspective shaped her leadership style.What it takes to commercialise complex therapies – lessons from inside large pharma, mid-stage biotechs, and early-stage ventures.The clinical data that changed everything – and how early adopters leveraged compassionate use to gain momentum.What’s next for EPIC Theranostics – and why workforce readiness and isotope supply could make or break the sector.If you're in biotech, pharma, or medtech, this episode is a masterclass in strategic thinking and scientific depth. Watch now and get ahead of where oncology is going.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDanielle MeyrickCo-Founder + Director At EPIC Theranostiocs LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings06:12 Nuclear Medicine09:26 Characteristics of a Good Drug Developer14:13 Future of Radiotheranostics20:05 Approaching Challenges26:52 Advice29:25 Motivations30:56 Greatest Achievements#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

Two of the most influential minds in immuno-oncology walk into a biotech… and build something that could change everything.Dr. Rachel Humphrey (CEO) and Dr. Melinda Merchant (CMO) of Normunity are two of the most seasoned and respected leaders in oncology drug development, with a combined 45+ years of experience across big pharma, biotech, and translational science. Rachel led the development of Yervoy® (ipilimumab) at BMS, Imfinzi® (durvalumab) at AstraZeneca, and Nexavar® (sorafenib) at Bayer, before holding CMO roles at Black Diamond, Mirati, and CytomX. Melinda, an immunologist and dual board-certified pediatric oncologist, spent a decade leading clinical studies at NIH and Memorial Sloan Kettering, running early trials of ipilimumab, nivolumab, and novel cell therapies before moving to industry and leading clinical development efforts of multiple investigational new drugs. Together, they now lead Normunity, where they’re pioneering a bold new therapeutic category: immune normalizers - designed to unlock immune resistance and open up new frontiers in cancer treatment.In this episode, we cover:- How Normunity is redefining immuno-oncology with its first-in-class T-cell engager- What it takes to build scientific teams that challenge each other - and still move fast- Lessons from launching Yervoy, Imfinzi, Tazverik, and other breakthrough therapies- Why biotech culture needs both humility and ego to succeed- What’s next as Normunity prepares to enter the clinic with NRM-823If you're a life sciences leader, founder, or investor - this conversation is essential listening. Tap in to hear what it really takes to build, lead, and scale science that matters.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.comYoutube: https://www.youtube.com/@life_sciencesRachel HumphreyCEO at NormunityLinkedIn: https://www.linkedin.com/in/rachel-w-humphrey-md-116b211b/Melinda MerchantCMO at NormunityLinkedIn: https://www.linkedin.com/in/melinda-merchant-7b496a/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings16:58 Traits of a Drug Developer19:53 Leadership in Biotech27:28 Story Behind Normunity30:23 Normunity Culture32:28 Mindsets in Translational Science36:33 Personal Life#LeadingBeyondTheLab #ARTOTalent #Biotechnology Hosted on Acast. See acast.com/privacy for more information.

Dr. Arndt Schottelius, CEO of Maxion Therapeutics, is a physician-scientist with a standout career across Genentech, MorphoSys, Kymab, and now at one of the UK’s most promising biotech companies. At Maxion, he leads a team pioneering KnotBody technology - an innovative approach to targeting ion channels and GPCRs, long considered “undruggable” with biologics. Arndt brings more than 25 years of experience across translational science, drug development and leadership in global R&D. His conviction, clarity, and track record - including developing molecules that have become partnered, acquired and approved - makes this conversation a must-listen for anyone in life sciences leadership.In this episode, we cover:How Maxion is building a new therapeutic modality using KnotBody technology to tackle autoimmune and inflammatory diseasesWhy conviction, speed, and storytelling are non-negotiable in translational drug developmentLessons from Genentech, MorphoSys, and Kymab on building pipelines, teams, and partnershipsWhat investors really look for - and how Maxion secured a competitive Series A in a tough marketHow to hire and scale for scientific excellence without losing agility or collaborationTune in for a dynamic, insightful conversation with one of biotech’s most experienced and thoughtful leaders.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentArndt SchotteliusCEO at Maxion TherapruticsLinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings06:46 Translational Science08:55 Lessons in Biotech Leadership25:23 Maxion - Culture and Roundup#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

If you want to understand what it really takes to build and lead a successful biotech, this episode is for you.Dr. Christopher Morabito, Chief Medical Officer at Astria Therapeutics, joins us to share hard-won lessons from 25 years in rare disease, oncology, and immunology. But this isn’t a career retrospective - it’s a deep dive into the mindset, strategies, and leadership habits that drive biotech success.In this episode, Chris reveals:How to make tough go/no-go decisions when the data isn’t clear.The leadership traits that keep teams aligned, motivated, and resilient in high-pressure environments.Why clarity of purpose matters more than anything else in a biotech’s mission.How to navigate the tension between scientific ambition and commercial reality.The patterns he’s seen across programs that make it from idea to approval.Chris distills decades of experience into practical, actionable advice for founders, executives, and investors - making this one of the most insightful conversations we’ve had yet.🎧 Tune in for a rare, candid look at biotech leadership from someone who’s been on the front lines of game-changing therapies.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentChristopher MorabitoCMO at Astria TherapeuticsLinkedIn: https://www.linkedin.com/in/chrismorabito/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings13:40 Moving Into Biotech23:34 Leading in Biotech28:41 Patients First38:23 Lessons & Legacy#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

If you're in biotech, immunology, or drug development - this is the episode you’ve been waiting for.We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene.In this episode, Bhaskar dives deep into:· How Triveni is building a first-in-class pipeline targeting the kallikrein system - a bold bet to treat severe skin and inflammatory conditions by tackling novel biology.· What it means to be a founder’s CMO, and how great science needs the right development strategy to make a difference.· Candid stories from his past roles at Nimbus (which sold its TYK2 program to Takeda for $4B) and Janssen, where he helped guide first-in-class therapies from Phase 1 to pivotal trials.· Why bispecifics may be risky but worth it, and how Triveni is using novel biologics to crack tough diseases like atopic dermatitis.· Advice for executives: how to balance ambition and discipline, when to say no, and why choosing the right team members matters as much as the science.🎙 Bhaskar doesn’t just talk science - he connects molecular biology to patient need, clinical strategy, and company vision with clarity and purpose.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentBhaskar Srivastava CMO at Triveni BioLinkedIn: https://www.linkedin.com/in/bhaskar-srivastava-355a9ab1/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings15:44 Success & Growth in Biotech28:43 Investing in Biotech34:23 The Future of Dermatology & Triveni Bio#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

If you care about the future of genomics, diagnostics, and biotech investing, you can’t miss this episode.We’re joined by Mara Aspinall, Partner at Illumina Ventures, a trailblazer with over 30 years of leadership in diagnostics and eight years in venture capital funding groundbreaking genomics companies.In this episode, Mara reveals:The next wave of diagnostics, from liquid biopsies to home testing and new AI-driven tools.Hard-won lessons from leading Genzyme Genetics, Roche Tissue Diagnostics, and building her own startup.Insider tips for founders on pitching, choosing the right investors, and building winning teams.A glimpse into where genomics is heading in the next decade - from neurodegenerative disease detection to early metabolic disease diagnostics.With her unmatched experience as an operator, educator, and investor, Mara brings clarity, energy, and vision to a fast-changing field. This conversation is packed with takeaways for founders, investors, and anyone fascinated by the future of healthcare.🎧 Tune in now for a masterclass in diagnostics, genomics, and venture capital from one of the industry’s most influential voices.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentMara AspinallPartner At Illumina VenturesLinkedIn: https://www.linkedin.com/in/mara-aspinall-6688142/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings04:10 Current Diagnostic Trends20:48 The Founder Investor Fit25:37 Genetics & Genomics29:06 Mara Aspinall39:31 Neurodegenerative Disease#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

To anyone interested in life science VC investment – you need to watch this.In this episode, we’re joined by Dr. Sascha Berger, a biotech investment director based in Saudi Arabia and a very experienced life science investor globally. With nearly two decades in the industry, he’s seen breakthroughs, pivots, and billion-dollar transactions.He reveals:Saudi Arabia’s high-stakes plan to become a global biotech superpower by 2040 - and why it could disrupt the industry as we know it.The real role of a VC beyond the money - how top investors become game-changing partners for founders.Raw stories from the front lines - startups on the brink of collapse that fought back to success.No-fluff advice for first-time founders on building the right team and surviving the brutal biotech rollercoaster.A global insider’s view on the next wave of innovation - from Boston’s biotech streets to the Middle East’s rising hubs.This is one of our most unfiltered and insightful episodes yet - a must-watch for founders, investors, or anyone who wants to see where life sciences is really heading.🎧 Tune in now to hear how a leading investor is driving biotech’s next era.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentSascha BergerSaudi Arabia Biotech InvestorLinkedIn: https://www.linkedin.com/in/sasber/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings08:04 Investing in Success26:13 Saudi Arabia - The Future36:29 How to Secure Investment#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Dr. Tomoko Maeda-Chubachi - a global leader in dermatology drug development and biotech innovation:Dr. Maeda-Chubachi serves as fractional Chief Medical Officer at various startups focusing on dermatology indications.20+ years experience in the pharmaceutical industry, Dr. Maeda-Chubachi has held senior roles at major companies like Pfizer, Eli Lilly, and GSK. Her expertise spans the entire drug development process, from early-phase trials to regulatory approvals.Tomoko has multiple notable achievements, she led the FDA approval of Zelsuvmi, helped secure a $250M deal for Vtama, and was named one of 2023’s top CMOs to watch.Dr. Maeda-Chubachi is a sought-after speaker, having presented at events like the Dermatology Drug Development Summit and the Japan Biotech Panel. She is also an active member of Women In Bio, receiving the Long Tenure Active Member Award from the RTP chapter.In this episode, we discuss a range of topics, including her career beginnings, challenges that come with drug development, leadership in biotech, key achievements and much more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentTomoko Maeda-ChubachiCMO at Kalm Therapeutics + Boardroom Ready at Women in BioLinkedIn: https://www.linkedin.com/in/tomoko-maeda-chubachi/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings06:23 Drug Development08:59 Leadership13:58 Achievements + Fractional CMO #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Nicholas Reder, who’s pushing the boundaries in AI-driven spatial tissue analysis, with a mix of experience and insights:Nick is the Founder & CEO at Alpenglow Biosciences, pioneers in AI-powered 3D spatial biology that transforms how we see and understand tissue biopsies.10+ years in translational research, with degrees in biochem, epidemiology, and medicine – plus a residency and fellowship in pathology at the University of Washington.Co-developed a groundbreaking open-top light-sheet microscope – now the core of Alpenglow’s tech.Nick is a major conference speaker at AACR, SID, PMWC, NextGen Omics, BIO International and more, and has won the Castleman Award - the highest global honour for pathologists under 40.In this episode, we discuss a range of topics including Alpenglow’s current success and what the future looks like, hiring talent within techbios, as well and leadership challenges within the computational biology space. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentNicholas RederFounder + CEO at Alpenglow BiosciencesLinkedIn: https://www.linkedin.com/in/nicholas-reder-210a578b/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings & Alpenglow04:54 AI & Hiring Talent14:58 Challenges / Key Triggers When Hiring19:36 Alpenglow Biosciences24:14 What’s Next - Quickfire Round#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Dr. Bernardo Cervantes, leading the charge in microbiome science, with a mix of experience and insights:Bernardo is the Co-Founder and COO of Concerto Biosciences, a biotech pioneering the development of microbial consortia-based therapeutics.With a robust background in microbial engineering, Bernardo has dedicated his career to studying microbial interactions and microbiome health. His expertise spans sythetic biology and metabolic engineering.Bernardo is internationally recognised for his contributions to microbiome science, particularly in translating complex microbial ecology into practical applications. His work at Concerto Biosciences has positioned him as a thought leader in developing next-generation microbial therapeutics.Prior to co-founding Concerto Biosciences, Bernardo earned his PhD in Microbiology from the Massachusetts Institute of Technology (MIT).Concerto has been active at major scientific conferences, including the 2024 BIO International Convention, where Concerto Biosciences was featured in the NIH Innovation Zone.In this episode, we discuss the future of microbiome sciences, Bernardo’s key learnings throughout his career, how he’s adapted his leadership as one of three Co-Founders, management, a great opportunity within the market and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Bernardo CervantesChief Operations Officer at Concerto BiosciencesLinkedIn: https://www.linkedin.com/in/bernacularbio/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings & Concerto Biosciences10:16 Concerto Biosciences - Key Learnings 15:26 Team Building & Culture 23:52 Quickfire Questions #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Dr. Frank Watanabe, a titan of biotech and pharma, and leader shaping the future of medicine:CEO of Arcutis Biotherapeutics, one of the few commercial stage Dermatology focused Biopharma companies; leading them from startup to IPO to commercial success.25+ years in biotech and pharma with expertise across of various Therapeutic areas.Proven leader in life sciences, known for building and scaling companies from early-stage to FDA approval - with leadership forged from time spent in the U.S. Navy.Former roles at Kythera, Lilly Amgen, and Allergan - driving strategy, R&D, and game-changing product launches.Champion of innovation, access, and purpose-driven leadership across the biopharma ecosystemIn this episode, we discuss everything from How Frank built Arcutis, motivation and Self-Improvement that is grounded from his experience in the Navy, revealing the key to success as a leader in the industry. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Frank WatanabePresident, CEO At ArcutisLinkedIn: https://www.linkedin.com/in/frank-watanabe-419711/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings + Arcutis05:01 Leadership & Growth20:52 Motivation & Self Improvement27:40 Personality Traits To Succeed In Pharma33:30 What’s Next For Arcutis#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Dr. Volker Koscielny, a distinguished figure in the pharmaceutical industry, with a wealth of experience and a forward thinking approach to medical innovation:CMO at Almirall, a global pharmaceutical company specialising in medical dermatology, dedicated to developing innovative treatments for skin diseases.20+ years of experience in dermatology, bridging between R&D, business development, marketing, and sales.Recognised globally for his commitment to understanding patient needs and demonstrating the real-world value of medicines.Former roles at Celgene, GlaxoSmithKline, Pfizer, Servier and Boehringer Ingelheim, leaving Volker with the experience to lead and scale cross-functional teams ensures the seamless integration of regulatory, clinical, and commercial strategies. Volker recently contributed to Almirall’s 15th annual Skin Academy, a conference that brings together dermatologists from across Europe to discuss advancements in inflammatory skin diseases and patient well-being.In this episode, we discuss the future of dermatology, Volker’s insights from industry roundtables, and the key experiences and achievements that shaped his success in the field. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Volker KoscielnyChief Medical Officer at AlmirallLinkedIn: https://www.linkedin.com/in/volker-koscielny/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Leadership In Life Sciences10:40 Potential In Dermatology16:21 Functionality As A Leader 22:40 Achievements & Wrapping Up #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Dr. Brian Kim, a true trailblazer at the cutting edge of science and medicine:Co-Founder at Alys Pharmaceuticals, a biopharmaceutical company with an innovation focus on immuno-dermatology, redefining how we understand chronic itch and skin inflammation. Brian is also the Director of the Mark Lebwohl Center for Neuroinflammation and Sensation and the Allen Discovery Center for Neuroimmune Interactions.Sol and Clara Kest Professor and Vice Chair of Research in Dermatology at Icahn School of Medicine at Mount Sinai.Nearly two decades of experience spanning dermatology, immunology, allergy and neuroscience.Internationally recognised for unlocking the mysteries of itch biology, opening doors to entirely new therapeutic approaches.Previously the Co-Founder of Nuogen Pharma and now on the scientific advisory board for Attovia Therapeutics and Triveni Bio. Brian is also an advisor for Septerna - helping to translate scientific insights into next-generation therapies. Recent keynote speaker at the prestigious Friedman Brain Institute’s Neuroscience Retreat, as well as plenary talks across both allergy and dermatology like the American Academy of Allergy, Asthma, and Immunology (AAAAI) Presidential Plenary Session (2/23/2024) and the Marion B. Sulzberger, MD Memorial Award and Lectureship at the American Academy of Dermatology March of 2024 - proving how his work resonates across disciplines.In this episode, we discuss everything from Innovation & AI in dermatology to Leadership in Academia vs Industry. Brian also reveals the reason Dermatology is securing so much funding in 2025. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership. Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Brian KimCo-Founder At Alys PharmaceuticalsLinkedIn: https://www.linkedin.com/in/brian-s-kim-4605662/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Innovation & AI11:08 Communication & Motivation23:58 Leadership in Industry VS Academia 35:32 Why Dermatology Secures Funding49:29 Quickfire Questions #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology #Immunology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Dr. Juergen Reess, a Board-Certified Neurologist with an incredible career spanning over 20 years in corporate and drug development leadership roles at Boehringer Ingelheim. After an extensive career in big pharma, Juergen transitioned into the world of biotech, where he now plays a pivotal role in shaping the future of medicine.Juergen is the Founder & CEO of MoglingBio Inc, an innovative company in the longevity space, pioneering novel pharmacological approaches to rejuvenate old stem cells, a field with immense potential. As well as this, Juergen is also the Fractional CMO of SciRhom, a Munich-based clinical-stage biotech tackling autoimmune diseases with iRhom2-targeting therapies, where they have just secured a €63M Series A funding round to propel their groundbreaking work.In this insightful conversation, we explore, how Juergen kick-started his career in life sciences, how he kept his career "fresh" in a big pharma setting by taking on new challenges, the challenges and adaptions from transitioning from big pharma to biotech, lessons from founding and funding his own biotech ventures, what "Longevity" really means in the biotech world, how he adapts across various therapeutic areas and much more.This episode is packed with valuable insights for anyone in life sciences, whether you're a scientist, entrepreneur, investor, or industry leader. Don't miss this inspiring discussion on innovation, adaptability, and leadership in biotech!Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Juergen ReessLinkedIn: https://www.linkedin.com/in/juergen-reess-b443468/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings 10:23 Shifting to Biotech16:13 Founding a Biotech21:15 Communicating with Investors24:41 AI in Life Sciences #LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Neurology Hosted on Acast. See acast.com/privacy for more information.

In this episode, our guest is Dr. Ingmar Bruns, M.D., Ph.D., a pioneer in biotech leadership and hematologist/oncologist. Dr Bruns is the Executive VP and CMO at Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We discuss Ingmar's breadth of experience in academia, where he studied medicine at both the Medical University of Vienna, as well as the Universität zu Lübeck, He then spent many years at both the University of Düsseldorf and the Albert Einstein College of Medicine.We discuss a variety of topics including Ingmar’s successes and mistakes, drug development, golden rules for biotechs, as well as fundraising in the life science industry. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Ingmar Bruns LinkedIn: https://www.linkedin.com/in/ingmar-bruns-9abb5446/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings12:12 Key Accomplishments and Reflections20:50 Persistence in Drug Development27:52 Identifying Differentiators in Biotechs38:00 Communicating with Investors53:17 Traits of Effective Leadership#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Hematology Hosted on Acast. See acast.com/privacy for more information.

In this episode, our episode is Dr. Christophe Giot, a highly accomplished global executive with a foundation as a clinical cardiologist and extensive experience in Clinical and Medical Affairs across diverse therapeutic areas including cardiology (interventional cardiology, structural heart), vascular diseases, interventional oncology, urology, immunology, and rare diseases. Dr. Giot is the CMO and VP Clinical Affairs at Affluent Medical, and attended Université libre de Bruxelles to study Cardiology and become a MD. We discuss how Christophe kick-started his career in the Life Science Industry, before transitioning to Pharma, as well as the key achievements and milestones he made along the way.Dr. Christophe Giot delivers a combination of stories and insights, including discussion on soft skills, communicating with investors, team building, AI in Pharma, the power of networking, onboarding, and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Cristophe GiotLinkedIn: https://www.linkedin.com/in/christophegiot/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings08:03 Transitioning to Industry14:27 Communicating with Stakeholders16:36 The Role of AI in Pharma19:19 Hiring and Onboarding Best Practices#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Cardiology Hosted on Acast. See acast.com/privacy for more information.